The core activity of CIS BIOPHARMA AG is the development and research of cancer therapies, with the goal of developing more effective treatment methods for cancer patients and improving their quality of life.
AI-generated
Offering
Products & services
Industry:Pharmaceutical Industry
✓ Offered8
Cancer Therapies
Targeted cancer therapies for aggressive tumors with high medical need, in particular small cell lung cancer, glioblastoma and brain metastases; based on antibody, nanobody and radioligand approaches.
Antibody-Drug-Conjugates (ADCs)
Antibody-drug conjugates for the targeted delivery of cytotoxic payloads to tumor cells; using CD171/L1CAM as the target structure, including CBO-001 for small cell lung cancer.
Nanobody-Drug-Conjugates (NDCs)
Nanobody-drug conjugates for targeted tumor treatment, in particular against CD276/B7H3; with programs for brain metastases and glioblastoma.
Radioligand Therapies (RLTs)
Targeted cancer treatments using a ligand and a radioisotope for the selective irradiation of tumor cells; implemented in the CBO-003 program against glioblastoma.
Bioconjugation platform
Platform for the development of targeted cancer therapies with protein engineering, linker chemistry and bioconjugation; includes targeting moieties, linker technology and payloads.
Outbound Leads by COHAGA
Looking for direct email addresses and phone numbers?
Leadhub delivers verified contact details and decision-makers from over 750,000 Swiss companies — management, procurement, marketing, HR.